NCT05385549 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
| NCT ID | NCT05385549 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Asan Medical Center |
| Condition | Gastrointestinal Stromal Tumors |
| Study Type | INTERVENTIONAL |
| Enrollment | 35 participants |
| Start Date | 2022-09-07 |
| Primary Completion | 2030-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 35 participants in total. It began in 2022-09-07 with a primary completion date of 2030-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this study, the investigators aim to investigate the efficacy and safety of 5 years of adjuvant imatinib treatment in patients with tumor rupture defined by Nishida classification or those with a tumor size 10cm or larger and a mitotic index of 10/50HPFs or higher.
Eligibility Criteria
Inclusion Criteria: 1. Age 20 years or older, at the time of acquisition of informed consent 2. Histologically confirmed GIST with CD117(+), DOG-1(+), or mutation in KIT or PDGFRα gene 3. (1) Completely resected localized GIST (R0 resection) within 12 weeks prior to the start of the adjuvant imatinib. (2) After complete resection(R0 resection), High risk GIST according to Modified NIH criteria and ongoing adjuvant imatinib treatment. 4\) High risk GIST according to Modified NIH criteria, 1. Tumor rupture according to Nishida classification or 2. tumor size \>10cm and mitosis \>10/50 HPF 5) Eastern Cooperative Oncology Group (ECOG) performance status 0 \~ 2 6) Adequate bone marrow, hepatic, renal, and other organ functions, before adjuvant imatinib treatment * Neutrophil \>1,500/mm3 * Platelet \> 100,000/mm3 * Hemoglobin \>8.0 g/dL * Total bilirubin \< 1.5 x upper limit of normal (ULN) * AST/ALT \< 2.5 x ULN * Creatinine \<1.5 x ULN 7) Provision of a signed written informed consent Exclusion Criteria: 1. Women of child-bearing potential who are pregnant or breast feeding 2. Women or men who are not willing to use effective contraception entering the study period or until at least 3 months after the last study drug administration. 3. If any of the following applies within ≤ 6 months prior to starting study enrollment : Myocardial Infarction, severe instable angina, coronary/peripheral bypass, NYHA class III or IV congestive heart failure, stroke or transient ischemic attack, treatment required severe arrhythmia. 4. Uncontrolled infection 5. Acute and chronic liver disease and all chronic liver impairment.(But Patients with stable chronic hepatitis B are eligible) 6. Patients who had reduced the dose of imatinib to less than 300 mg/day due to toxicity. 7. Acute, or chronic medical or psychiatric condition or laboratory abnormality such as active uncontrolled infection that difficult to study participation in the judgment of the investigator 8. Known diagnosis of HIV infection (HIV testing is not mandatory). 9. History of another primary malignancy that is currently clinically significant or currently requires active intervention. 10. Alcohol or substance abuse disorder. 11. The patients with PDGFRα D842V mutation
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05385549 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying Gastrointestinal Stromal Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05385549 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT05385549 currently recruiting?
Yes, NCT05385549 is actively recruiting participants. Contact the research team at miniryu@amc.seoul.kr for enrollment information.
Where is the NCT05385549 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT05385549 clinical trial?
NCT05385549 is sponsored by Asan Medical Center. The trial plans to enroll 35 participants.